Effective Protection

A simple vaccination is the best way to help protect your child against meningococcal disease1

No one likes to think about their child or loved one getting meningococcal disease. Fortunately, Menveo® is at the frontlines in the fight against this deadly illness—helping to provide an effective defense for those at risk.2

 

Many strains of meningococcal bacteria

Meningococcal disease is caused by Neisseria meningitidis, more commonly known as meningococcal bacteria. It is the leading cause of bacterial meningitis in adolescents and is passed through saliva or respiratory and throat secretions.1,3 It can also cause a serious blood  infection known as meningococcemia.4

The specific strains responsible for the majority of cases in the United States and around the world are known as A, C, Y, W-135 and B. The Menveo vaccine helps protect against 4 of the 5 strains of this bacteria – known as A, C, Y, and W-135.1,2    

Indication

Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 2 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.

Important Safety Information

You should not receive Menveo if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as Menveo.

Side effects to Menveo include pain at the injection site, headache, muscle pain, fatigue, nausea, and fainting. Sometimes fainting is accompanied by falling with injury. Other side effects may occur.

Following vaccination with another US-licensed meningococcal conjugate vaccine, an evaluation of postmarketing adverse events suggested a potential for increased risk of Guillain-Barré Syndrome (GBS). There is not enough information to evaluate if a risk of GBS exists following administration of Menveo.

Tell your doctor if you are pregnant or planning to get pregnant.

Vaccination with Menveo may not protect all individuals.

For more information about Menveo, talk to your health-care professional.

Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.

References

  1. Meningococcal: Questions and answers. Immunization Action Coalition Web site. http://www.immunize.org/catg.d/p4210.pdf. Accessed March 3, 2010.
  2. Menveo [prescribing information]. Cambridge, MA: Novartis Vaccines and Diagnostics Inc; 2010.
  3. Meningococcal vaccines: What you need to know. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-mening.pdf. Accessed February 18, 2010.
  4. Meningitis: Signs & symptoms. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/about/symptoms.html. Accessed February 18, 2010.

Menveo.com Exit Notice

You are now leaving the Menveo.com site and moving to an external website independently operated and not managed by Novartis Vaccines and Diagnostics Inc. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or, click OK to continue.

OKCancel